Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer

NCT01815242 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

336

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: nab-Paclitaxel
DRUG: Gemcitabine
DRUG: Carboplatin

Sponsor

West German Study Group

Collaborators

[object Object]